The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background There is a need for a reliable and inexpensive noninvasive marker of hepatic fibrosis in nonalcoholic fatty liver disease (NAFLD). Aim To compare the performance of the FIB4 index (based on age, aspartate and alanine aminotransferase and platelet counts) with six other non-invasive markers of fibrosis in patients with NAFLD. Methods Using a nation-wide database of 541 adults with NAFLD, jackknife-validated areas under receiver operating characteristic curves (AUROC) of FIB4 and seven other markers were compared. The sensitivity at 90% specificity, 80% positive predictive value, and 90% negative predictive values were determined along with cutoffs for advanced fibrosis. Results The median FIB4 score was 1.11 (IQR=0.74–1.67). The jackknife-validated AUROC for FIB4 was 0.802 (95% CI: 0.758, 0.847) which was higher than that for the NAFLD fibrosis score (0.768 CI:0.720–0.816, p= 0.09), Goteburg University Cirrhosis Index (0.743, CI:0.695–0.791, p< 0.01), AST:ALT ratio (0.742, CI:0.690–0.794, p< 0.015), AST to platelet ratio index (0.730, CI:0.681–0.779, p< 0.001), AST to platelet ratio (0.720, 0.669–0.770, p< 0.001), BARD score (0.70, p< 0.001) and cirrhosis discriminant score (0.666, CI:0.614–0.718, p< 0.001). For a fixed specificity of 90% (FIB4 = 1.93), the sensitivity of identifying advanced fibrosis was only 50% (95% CI: 46, 55). A FIB4 ≥ 2.67 had an 80% positive predictive value and a FIB4 index ≤ 1.30 had a 90% negative predictive value. Conclusions The FIB4 index is superior to seven other non-invasive markers of fibrosis in patients with NAFLD; however its performance characteristics highlight the need for even better non-invasive markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationHanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,077
Cited by
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citation(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
“In patients with NAFLD, the NAFLD fibrosis score [40] is currently the most studied [85,113–118] and validated biomarker [119].”
BackgroundNonalcoholic Steatohepatitis: A Review
Sheka, A. C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020) · JAMA · doi:10.1001/jama.2020.2298 · Cited by 1,379
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Lin, Z.-H., Xin, Y.-N., Dong, Q.-J., Wang, Q., Jiang, X.-J., Zhan, S.-H., Sun, Y., & Xuan, S.-Y. (2011) · Hepatology · doi:10.1002/hep.24105 · Cited by 1,067
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
“Among 14 serum-based biomarker panels for hepatic fibrosis, the FibroTest,(247-249) the serum AST/platelet ratio index (APRI),(250) the Fibrosis-4 index (FIB-4),(251,252) and the enhanced liver fibrosis test(253,254) have emerged as the better candidates in AIH.”
BackgroundMcPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., & Day, C. P. (2010) · Gut · doi:10.1136/gut.2010.216077 · Cited by 946
Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Sumida, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.475 · Cited by 689
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Wong, V. W.-S., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Li, M. K.-P., Chan, H.-Y., Chim, A. M.-L., Yu, J., Sung, J. J.-Y., & Chan, H. L.-Y. (2010) · Gut · doi:10.1136/gut.2009.205088 · Cited by 648
Vilar-Gomez, E., & Chalasani, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 610
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324243 · Cited by 556
JSG-NAFLD, Eguchi, Y., Hyogo, H., Ono, M., Mizuta, T., Ono, N., Fujimoto, K., Chayama, K., & Saibara, T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0533-z · Cited by 551
Vajro, P., Lenta, S., Socha, P., Dhawan, A., McKiernan, P., Baumann, U., Durmaz, O., Lacaille, F., McLin, V., & Nobili, V. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318252a13f · Cited by 528
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Self-citationAngulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502
Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M., Valasek, M., Lin, G., Brenner, D., Gamst, A., et al. (2014) · Hepatology · doi:10.1002/hep.27362 · Cited by 489
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
Gaggini, M., Carli, F., Rosso, C., Buzzigoli, E., Marietti, M., Della Latta, V., Ciociaro, D., Abate, M. L., Gambino, R., Cassader, M., et al. (2018) · Hepatology · doi:10.1002/hep.29465 · Cited by 465
Clinical, Laboratory and Histological Associations in Adults with Nonalcoholic Fatty Liver Disease†
Neuschwander-Tetri, B. A., Clark, J. M., Bass, N. M., Van Natta, M. L., Unalp-Arida, A., Tonascia, J., Zein, C. O., Brunt, E. M., Kleiner, D. E., McCullough, A. J., et al. (2010) · Hepatology · doi:10.1002/hep.23784 · Cited by 463
Self-citationMetabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Use of Liver Imaging and Biopsy in Clinical Practice
Tapper, E. B., & Lok, A. S.-F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1610570 · Cited by 442
Younossi, Z. M., Loomba, R., Anstee, Q. M., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., et al. (2018) · Hepatology · doi:10.1002/hep.29721 · Cited by 431
Self-citationKim, D., Konyn, P., Sandhu, K. K., Dennis, B. B., Cheung, A. C., & Ahmed, A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.035 · Cited by 412
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., Kanemasa, K., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-2 · Cited by 383
Allen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S. (2018) · Hepatology · doi:10.1002/hep.29546 · Cited by 370
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 357
Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, A. W.-H., Chermak, F., Choi, P. C.-L., Merrouche, W., Chu, S. H.-T., Pesque, S., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.331 · Cited by 345
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
Muzurović, E., Mikhailidis, D. P., & Mantzoros, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 336
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationKanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 306
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology · doi:10.1002/hep.30842 · Cited by 277
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273
Noninvasive evaluation of NAFLD
Castera, L., Vilgrain, V., & Angulo, P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.175 · Cited by 273
Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage
Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.031 · Cited by 272
Self-citationReal-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
Alexander, M., Loomis, A. K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1103-x · Cited by 272
Advances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 264
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Liver fibrosis scores predict liver disease mortality in the United States population
Unalp‐Arida, A., & Ruhl, C. E. (2017) · Hepatology · doi:10.1002/hep.29113 · Cited by 260
Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257
“org Obesity | VOLUME 27 | NUMBER 1 | JANUARY 2019 43 suggestive of advanced fibrosis (17,18).”
BackgroundJones, H., Sprung, V. S., Pugh, C. J. A., Daousi, C., Irwin, A., Aziz, N., Adams, V. L., Thomas, E. L., Bell, J. D., Kemp, G. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1382 · Cited by 256
Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K., & Sanyal, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.013 · Cited by 236
Self-citationImpact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00141-3 · Cited by 214
Collagen biology and non‐invasive biomarkers of liver fibrosis
Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International · doi:10.1111/liv.14390 · Cited by 197
Younes, R., Caviglia, G. P., Govaere, O., Rosso, C., Armandi, A., Sanavia, T., Pennisi, G., Liguori, A., Francione, P., Gallego-Durán, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.008 · Cited by 196
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
“(6,7) However, cardiovascular disease (CVD) remains the most common cause of mortality and morbidity in patients with NAFLD.”
BackgroundMethodInfluentialSerum Immunoglobulin Levels Predict Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
McPherson, S., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.010 · Cited by 124
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Cholankeril, G., Kramer, J. R., Chu, J., Yu, X., Balakrishnan, M., Li, L., El-Serag, H. B., & Kanwal, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.035 · Cited by 119
Nonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
Luo, Y., Oseini, A., Gagnon, R., Charles, E. D., Sidik, K., Vincent, R., Collen, R., Idowu, M., Contos, M. J., Mirshahi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30457-y · Cited by 74
Self-citationChun, H. S., Lee, M., Lee, H. A., Oh, S. Y., Baek, H. J., Moon, J. W., Kim, Y. J., Lee, J., Kim, H., Kim, H. Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.043 · Cited by 60
Henry, A., Paik, J. M., Austin, P., Eberly, K. E., Golabi, P., Younossi, I., Henry, L., Gerber, L., & Younossi, Z. M. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17308 · Cited by 61
van Baar, A. C. G., Beuers, U., Wong, K., Haidry, R., Costamagna, G., Hafedi, A., Deviere, J., Ghosh, S. S., Lopez-Talavera, J. C., Rodriguez, L., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.006 · Cited by 55
Self-citationBril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care · doi:10.2337/dc18-2578 · Cited by 52
Non-alcoholic fatty liver disease and its association with depression in Korean General Population
Jung, J. Y., Park, S. K., Oh, C.-M., Chung, P.-W., & Ryoo, J.-H. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e199 · Cited by 51
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Sinn, D. H., Kang, D., Cho, S. J., Paik, S. W., Guallar, E., Cho, J., & Gwak, G.-Y. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002158 · Cited by 37
Behari, J., Gougol, A., Wang, R., Luu, H. N., Paragomi, P., Yu, Y.-C., Molinari, M., Chopra, K., Malik, S. M., Geller, D., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000183 · Cited by 35
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27
Self-citationKashiwagi, K., Yamaguchi, A., Shiba, S., Taniki, N., Inoue, N., Takaishi, H., Iwao, Y., & Kanai, T. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.07.010 · Cited by 26
Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8939 · Cited by 23
Patient-centered care: Key elements applicable to chronic liver disease
Verma, M., Brahmania, M., Fortune, B. E., Asrani, S. K., Fuchs, M., & Volk, M. L. (2023) · Hepatology · doi:10.1002/hep.32618 · Cited by 24
Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality
Kim, D., Manikat, R., Shaikh, A., Cholankeril, G., & Ahmed, A. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14087 · Cited by 17
Beyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103513 · Cited by 13
“Age; BMI; DM status; AST, ALT, and albumin levels; and platelet count are used when calculating these scoring systems [26,27].”
Shiomi, M., Tanaka, Y., Takada, T., & Otori, K. (2020) · JGH Open · doi:10.1002/jgh3.12384 · Cited by 13
Metadata
- Authors
- Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1104-1112
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2081324449
- Cited by
- 1,553
- References
- 41
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.